002693 Hainan Shuangcheng Pharmaceuticals
- 4.50
- -0.08-1.75%
Hainan Shuangcheng Pharmaceuticals News
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Production license of Ningbo Shuangcheng Pharmaceuticals changed, involving an increase in entrusted production information.
On June 20th, Gelunhui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that its holding subsidiary, Ningbo Shuangcheng Pharmaceuticals Co., Ltd. ("Ningbo Shuangcheng"), had recently obtained a Drug Production License reissued by the Zhejiang Provincial Drug Administration. The matters involved in this change are: authorizing Ningbo Shuangcheng to add the name of the entrusted enterprise as Zhejiang Heze Pharmaceutical Technology Co., Ltd., with a production/registration address at Room 201, Building 4, No. 101, First Street, Xiasan Street, Qiantang District, Hangzhou City, Zhejiang Province, and the drug name as KY-XES with no approval number, registered in conjunction with the application (for registration application only).
Hainan Shuangcheng Pharmaceuticals' Q1 2024 Financial Report: Deep Dive into Financial Data.
Hainan Shuangcheng Pharmaceuticals (stock code: 002693) is a company that focuses on the research and development of chemically synthesized polypeptide drugs and is committed to promoting innovation in the polypeptide drug industry. The company occupies an important position in the medical industry, especially in the field of polypeptide drugs. In recent years, despite the challenges of economic downturn and policy adjustment in the medical industry, it has also ushered in new development opportunities. In 2023, the country will introduce multiple policies aimed at deepening the linkage reform of medicine, medical care, and medical insurance and promoting the healthy development of the industry. In particular, various guiding principles and management methods issued by the National Medical Products Administration provide development and business opportunities for Hainan Shuangcheng Pharmaceuticals in the future.
Hainan Shuangcheng Pharmaceuticals (002693.SZ): At present, the product Acotiamide Acetate Injection has not yet been launched for sale in the USA market.
On June 13th, Gelonhui reported that an investor asked Hainan Shuangcheng Pharmaceuticals (002693.SZ) on the investor interaction platform, "Has the Acetate Ornipressin Injection ANDA obtained FDA approval and been sold in the US market?" The company responded that its product, Acetate Ornipressin Injection, has not yet been launched for sale in the US market.
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Ningbo Shuangcheng Pharmaceutical Production License Changes.
On June 3, Gelunhui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that its controlling subsidiary, Ningbo Shuangcheng Pharmaceuticals Co., Ltd. (referred to as "Ningbo Shuangcheng"), recently obtained the "Drug Production License" issued by the Zhejiang Provincial Drug Administration. This change mainly involves the addition of pharmaceutical GMP compliance inspection for the capsule production line in Ningbo Shuangcheng's oral solid workshop. This change involves Pregabalin capsules. Pregabalin is a GABA analogue, a neurotransmitter, and a follow-up product to gabapentin. Currently, Pregabalin capsules are approved by the United States Food and Drug Administration (FDA).
[BT Financial Report Momentary Analysis] In-depth Analysis of Shuangcheng Pharmaceutical's 2023 Report: Financial Data Perspective
Shuangcheng Pharmaceutical (stock code: 002693), as an important member of China's pharmaceutical industry, has long been committed to the development and production of chemically synthesized peptide drugs. In recent years, it has faced new opportunities and challenges under the dual influence of industry policies and market environment. In 2023, Shuangcheng Pharmaceutical's financial report revealed the latest developments in the company's operating activities, balance and liability structure, profitability, etc., providing investors and market analysts with important financial information. Judging from balance and liability data, the total assets of Shuangcheng Pharmaceutical fell from 911 million yuan in 2022 to 803 million yuan in 2023, a decrease
Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3%
A production line of Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), passed the good manufacturing practices or GMP inspection of the drug regulator in Chi
Shuangcheng Pharmaceutical (002693.SZ): Ningbo Shuangcheng Oral Solids Workshop 1, capsule production line passed GMP compliance inspection
Gelonghui, May 21丨Shuangcheng Pharmaceutical (002693.SZ) announced that the company's holding subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd. (“Ningbo Shuangcheng”), learned from the Zhejiang Drug Administration website that Ningbo Shuangcheng Oral Solids Workshop 1. The capsule production line passed the GMP compliance inspection.
Zhitong A Share Sale Restriction Release List|May 13
According to the Zhitong Finance App, the ban on restricted shares of 30 listed companies was lifted on May 13, with a total market value of about 23.962 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Harbin Pharmaceutical shares 600664, share incentives, 1,531,000 Weixing shares 002003, share incentives, limited circulation, 6.942 million Lianchuang Electronics 002036, equity incentives, 5.651 million, Longyuan Technology 300105 share incentives, limited sales, circulation, 1.4411 million, Huapengfei 300350 share incentive circulation 220,08 Wan Jin Rongtian
Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US
Hainan Shuangcheng Pharmaceutical (SHE:002693) obtained marketing authorization from the US Food and Drug Administration for its octreotide acetate injection, according to a filing with the Shenzhen S
Shuangcheng Pharmaceutical (002693.SZ): Octreotide acetate injection ANDA obtained US FDA marketing approval
Gelonghui, May 6, 丨 Shuangcheng Pharmaceutical (002693.SZ) announced that the company recently received a notice from the US Food and Drug Administration (“FDA”). The simplified new drug application for octreotide acetate injection submitted by the company to the US FDA (“ANDA” for short) has been approved for marketing by the US FDA. The US FDA conducted a comprehensive technical review of the ANDA application data for octreotide acetate injection submitted by the company, and approved the comprehensiveness and scientific nature of the application information. Octreotide acetate injection is suitable for patients with acromegaly whose condition cannot be adequately controlled by controlled surgery or radiation therapy
Shuangcheng Pharmaceutical (002693.SZ): Net loss of 8.7427 million yuan in the first quarter
Gelonghui, April 29 | Shuangcheng Pharmaceutical (002693.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 42.7617 million yuan, a year-on-year decrease of 47.52%; net profit attributable to shareholders of listed companies - 8.7427 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 9.0527 million yuan; basic earnings per share - 0.0211 yuan.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) shareholders that were waiting for something to happen have been dealt a blow with a 28% share price drop in the last month. Instead of be
Shuangcheng Pharmaceutical (002693.SZ): Bortezomib for injection obtained drug registration certificate
Gelonghui, April 15 | Shuangcheng Pharmaceutical (002693.SZ) announced that the company recently received the “Bortezomib for Injection” and “Drug Registration Certificate” approved and issued by the State Drug Administration. The certificate number is 2024S00518. Bortezomib for injection is suitable for 1) treatment of patients with multiple myeloma who have not been treated previously and are not suitable for high-dose chemotherapy and bone marrow transplantation; or as a single agent for the treatment of patients with multiple myeloma who have recurred after receiving at least one or more treatments; 2) combined rituximab, cyclophosphamide, and doxorubicin
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules
Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), obtained approval from China's National Medical Products Administration to register pregabalin capsules for
Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia
Hainan Shuangcheng Pharmaceutical (SHE:002693) said it can now market its bivalirudin for injection in Saudi Arabia after receiving approval from the country's drug regulator, the pharmaceutical compa
Shuangcheng Pharmaceutical (002693.SZ): Changes in production license for holding subsidiary Ningbo Shuangcheng Pharmaceutical
Gelonghui, March 7, 丨 Shuangcheng Pharmaceutical (002693.SZ) announced that the company's holding subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd. (“Ningbo Shuangcheng”), recently obtained a “Pharmaceutical Production License” issued by the Zhejiang Drug Administration. This change mainly involves extending the contract production validity period of the contract company SC-C134 to November 13, 2027.
Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) With Shares Advancing 34%
Those holding Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) shares would be relieved that the share price has rebounded 34% in the last thirty days, but it needs to keep going to repair t
Insiders Were the Biggest Winners as Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Market Cap Grew by CN¥383m Last Week
Key Insights Insiders appear to have a vested interest in Hainan Shuangcheng Pharmaceuticals' growth, as seen by their sizeable ownership A total of 4 investors have a majority stake in the company
Shuangcheng Pharmaceutical (002693.SZ): Pharmaceutical production license change
Gelonghui, Feb. 6: Shuangcheng Pharmaceutical (002693.SZ) announced that the company recently obtained the revised “Pharmaceutical Production License” issued by the Hainan Drug Administration. The main matters involved in this change are: it was agreed that the company would increase the production scope at No. 16 Xingguo Road, Xiuying District, Haikou City: C144 (Second API Workshop, C144 Production Line for Polypeptide APIs), limited to registration and use; other details remained unchanged.
Shuangcheng Pharmaceutical (002693.SZ): Multiple peptide varieties (including APIs and formulations) have been approved and marketed in developed countries
Gelonghui January 31 丨 An investor asked Shuangcheng Pharmaceutical (002693.SZ) on the investor interactive platform, “Does the company have professional peptide formulation research and development capabilities? Or is it just OEM? “It does not have R&D capabilities,” the company replied that the company focuses on R&D, production and sales of peptide products. Multiple peptide varieties (including APIs and formulations) have been approved and marketed in developed countries, and the production site has also passed GMP inspections by the US FDA and the European Union. The company has rich experience in R&D, registration, production and marketing of chemically synthesized peptide drugs, and has successfully developed multiple chemical syntheses
Analysis
Price Target
No Data
